Losartan Potassium
Product Images NDC 53002-1624

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-1624). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure01 (Figure01)

A line graph comparing the percentage of patients with the primary endpoint over study months between Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents the study months up to 66, and the y-axis represents the percentage of patients. The graph also notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure02 (Figure02)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between two treatments: Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients with stroke (0 to 8%). Text on the graph states an Adjusted Risk Reduction of 25% with p=0.001.*

FDA Label Image

Figure03 (Figure03)

This figure presents hazard ratio plots comparing Losartan Potassium and Atenolol event rates across patient subgroups. Two outcome categories are shown: Primary Composite and Stroke (Fatal/Non-fatal). Patient characteristics analyzed include age, gender, race, ISH status, diabetes, and history of cardiovascular disease. Symbols indicate hazard ratios with confidence intervals, showing relative event risk between the two drugs.*

FDA Label Image

Figure04 (Figure04)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph shows two lines: a solid line for Losartan Potassium and a dotted line for placebo, indicating a risk reduction of 16.1% with p=0.022.*

FDA Label Image

Label Image (Lbl530021624)

Losartan Potassium 25 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets with directions to take 1 tablet daily or as directed. It includes NDC 53002-1624, barcode, and typical regulatory information such as lot number and expiration date.*

FDA Label Image

Structure (Structure)

Chemical structure of Losartan Potassium, showing the molecular arrangement with chlorine, hydroxyl group, and potassium ion depicted as part of the compound's structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.